Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-ANG3 in dyslipidemia and familial hypercholesterolemia
NCT03747224Phase 1Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- May 2021
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in dyslipidemia, familial hypercholesterolemia (FH) and hypertriglyceridemia comparing ARO-ANG3 with Placebo (2 arms). Primary endpoint: Adverse Events Possibly or Probably Related to Treatment at 113 days. Started Jan 2019; status: completed.
02
Drugs
zodasiran
03
Conditions
dyslipidemiafamilial hypercholesterolemia (FH)hypertriglyceridemia
Beyond the preview
Go deeper on NCT03747224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747224.